Literature DB >> 10439115

New clothes for amyloid enhancing factor (AEF): silk as AEF.

R Kisilevsky1, L Lemieux, L Boudreau, D S Yang, P Fraser.   

Abstract

Amyloid enhancing factor (AEF) is an activity that appears naturally during the course of persistent inflammation and precedes, by 24-48 h, AA amyloid deposition in appropriate murine models. AEF is defined by its biological properties, namely, when administered intravenously or intraperitoneally to a mouse, it primes the recipient for the rapid induction of AA amyloid when they are given an inflammatory stimulus. Available evidence indicates that AEF is protein in nature, but a specific molecular species (if a singular species exits) has not been identified. Past work (Ganowiak et al., Biochem. Biophys. Res. Commun. 199:306-312, 1994) has shown that AEF activity may be imparted to two different proteins (IAPP and beta-protein) provided each is organized in the form of an amyloid fibril. Since a characteristic property of proteins in amyloid fibrils is their beta-sheet organization, one possibility is that AEF activity, in part, depends on such organization, and other proteins with such properties may also have AEF activity. To investigate this possibility, silk, a protein which contains substantial beta-sheet content, was denatured in LiSCN and allowed to renature slowly under reducing conditions to form a gel. The denatured silk preparation was then sonicated thoroughly to permit intravenous injection and assessed for AEF activity. The modified silk, presented as small fibrils in a beta-sheet conformation as assessed by electron microscopy and circular dichroism, respectively. This silk at 0-50 micrograms/animal was administered intravenously as "AEF" followed immediately by subcutaneous AgNO3 as the inflammatory stimulus. Six days later the spleens were examined for the presence of AA amyloid and following Congo red staining, the amount of amyloid quantified by image analysis. Modified silk without an inflammatory stimulus, and non-sonicated modified silk, failed to induce AA amyloid. Sonicated modified silk followed by AgNO3 induced large quantities of splenic AA amyloid in a dose dependent fashion. Modified silk in quantities as small as 1-5 micrograms/animal can function as AEF. The AEF properties of the modified silk were stable at 4 degrees C for at least 4 weeks (the longest period tested). This procedure may provide a means of standardizing AEF preparations.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10439115     DOI: 10.3109/13506129909007309

Source DB:  PubMed          Journal:  Amyloid        ISSN: 1350-6129            Impact factor:   7.141


  13 in total

1.  Classical and alternative pathway complement activation are not required for reactive systemic AA amyloid deposition in mice.

Authors:  Winston L Hutchinson; Jeff Herbert; Marina Botto; Mark B Pepys
Journal:  Immunology       Date:  2004-06       Impact factor: 7.397

2.  Mutagenic exploration of the cross-seeding and fibrillation propensity of Alzheimer's beta-amyloid peptide variants.

Authors:  Alexander Peim; Peter Hortschansky; Tony Christopeit; Volker Schroeckh; Walter Richter; Marcus Fändrich
Journal:  Protein Sci       Date:  2006-06-02       Impact factor: 6.725

Review 3.  [Amyloid and amyloidoses].

Authors:  C Röcken; M Eriksson
Journal:  Pathologe       Date:  2009-05       Impact factor: 1.011

4.  Longitudinal study of experimental induction of AA amyloidosis in mice seeded with homologous and heterologous AA fibrils.

Authors:  Naeem Muhammad; Tomoaki Murakami; Yasuo Inoshima; Naotaka Ishiguro
Journal:  Inflamm Res       Date:  2016-05-10       Impact factor: 4.575

Review 5.  Amyloid fibril polymorphism: a challenge for molecular imaging and therapy.

Authors:  M Fändrich; S Nyström; K P R Nilsson; A Böckmann; H LeVine; P Hammarström
Journal:  J Intern Med       Date:  2018-02-19       Impact factor: 8.989

6.  Protein fibrils in nature can enhance amyloid protein A amyloidosis in mice: Cross-seeding as a disease mechanism.

Authors:  Katarzyna Lundmark; Gunilla T Westermark; Arne Olsén; Per Westermark
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-13       Impact factor: 11.205

7.  Inactivation of amyloid-enhancing factor (AEF): study on experimental murine AA amyloidosis.

Authors:  Masatoshi Omoto; Tadaaki Yokota; Dan Cui; Yoshinobu Hoshii; Hiroo Kawano; Toshikazu Gondo; Tokuhiro Ishihara; Takashi Kanda
Journal:  Med Mol Morphol       Date:  2007-06-18       Impact factor: 2.309

8.  Tissue distribution, biochemical properties, and transmission of mouse type A AApoAII amyloid fibrils.

Authors:  Tatsumi Korenaga; Xiaoying Fu; Yanming Xing; Takatoshi Matsusita; Kazunao Kuramoto; Seigo Syumiya; Kazuhiro Hasegawa; Hironobu Naiki; Masaki Ueno; Tokuhiro Ishihara; Masanori Hosokawa; Masayuki Mori; Keiichi Higuchi
Journal:  Am J Pathol       Date:  2004-05       Impact factor: 4.307

Review 9.  Microbial manipulation of the amyloid fold.

Authors:  William H DePas; Matthew R Chapman
Journal:  Res Microbiol       Date:  2012-10-27       Impact factor: 3.992

10.  Fibrils from designed non-amyloid-related synthetic peptides induce AA-amyloidosis during inflammation in an animal model.

Authors:  Per Westermark; Katarzyna Lundmark; Gunilla T Westermark
Journal:  PLoS One       Date:  2009-06-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.